Related content

The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study

By Garcia Esther  

CNS Drugs, Vol. 23, Iss. 7, 2009-07 ,pp. : 615-625

Adis International

Access to resources Recommend Favorite

Nicotine and Behavioral Markers of Risk for Schizophrenia - A Double-Blind, Placebo-Controlled, Cross-Over Study

By Depatie L.   O'Driscoll G.A.   Holahan A.-L.V.   Atkinson V.   Thavundayil J.X.   Kin N.N.Y.   Lal S.  

Neuropsychopharmacology, Vol. 27, Iss. 6, 2002-12 ,pp. : 1056-1070

Elsevier

Access to resources Recommend Favorite

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

By Poyurovsky Michael   Fuchs Camil   Pashinian Artashez   Levi Aya   Faragian Sarit   Maayan Rachel   Gil-Ad Irit  

Psychopharmacology, Vol. 192, Iss. 3, 2007-06 ,pp. : 441-448

Springer Publishing Company

Access to resources Recommend Favorite

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

By Poyurovsky M.   Koren D.   Gonopolsky I.   Schneidman M.   Fuchs C.   Weizman A.   Weizman R.  

European Neuropsychopharmacology, Vol. 13, Iss. 2, 2003-03 ,pp. : 123-128

Elsevier

Access to resources Recommend Favorite

Schizophrenia: Do we really need placebo-controlled studies?

By Storosum J.G.   Elferink A.J.A.   van Zwieten B.J.  

European Neuropsychopharmacology, Vol. 8, Iss. 4, 1998-12 ,pp. : 279-286

Elsevier

Access to resources Recommend Favorite